<DOC>
	<DOCNO>NCT02739997</DOCNO>
	<brief_summary>This Phase 3 , multi-site , non-randomized , open-label study evaluate safety efficacy MK-7625A 1.5 g ( ceftolozane 1 g/tazobactam 0.5 g ) plus metronidazole 500 mg treatment Complicated Intra-abdominal Infections ( cIAI ) Japanese participant . Efficacy primarily assess clinical response define complete resolution significant improvement sign symptom index infection .</brief_summary>
	<brief_title>Study Ceftolozane/Tazobactam ( MK-7625A ) Combination With Metronidazole Japanese Participants With Complicated Intra-abdominal Infection ( MK-7625A-013 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Has one follow diagnosis evidence intraperitoneal infection : cholecystitis ( include gangrenous cholecystitis ) rupture , perforation , progression infection beyond gallbladder wall ; diverticular disease perforation abscess ; appendiceal perforation periappendiceal abscess ; acute gastric duodenal perforation , traumatic perforation intestine ; peritonitis due perforate viscus follow prior operative procedure ; Intraabdominal abscess ( include liver spleen ) . Has evidence systemic infection Had plan surgical intervention within 24 hour first dose study drug Has radiographic evidence perforation abscess enrol preoperatively Is able intraabdominal specimen take baseline microbiological assessment Female participant child bear potential must pregnant ( negative human chorionic gonadotropin test ) breastfeeding must agree use adequate contraception duration study 35 day last dose study drug Male participant must agree use adequate contraception duration study 75 day last dose study drug Has simple appendicitis ; abdominal wall abscess ; small bowel obstruction ischemic bowel disease without perforation ; spontaneous bacterial peritonitis associate cirrhosis chronic ascites ; acute suppurative cholangitis ; infect necrotizing pancreatitis ; pancreatic abscess ; infectious mononucleosis ; cystic fibrosis ; pelvic infection Has complicate intraabdominal infection manage staged abdominal repair ( STAR ) open abdomen drainage Has acute gastric duodenal perforation ( ≤ 24 hour ) traumatic perforation intestine ( ≤ 12 hour ) operate perforation occur Is expect cured surgical intervention without use systemic antibacterial therapy Has use systemic antibacterial therapy intraabdominal infection 24 hour prior first dose study drug , unless document treatment failure therapy Has severe impairment renal function ( estimate CrCl &lt; 30 mL/minute ) , requirement peritoneal dialysis , hemodialysis hemofiltration , oliguria ( &lt; 20 mL/hour urine output 24 hour ) Has concomitant infection time randomization , require nonstudy systemic antibacterial therapy addition study drug exception antibacterial Grampositive activity ( vancomycin , teicoplanin , linezolid daptomycin ) Has use postoperative nonstudy antibacterial therapy enrol preoperatively Has use 1 dose nonstudy antibacterial therapy follow surgery enrol postoperatively Has hepatic disease Is unlikely survive 4 5 week study period Has organic brain spinal cord disease Has rapidlyprogressing disease immediately lifethreatening illness Has immunocompromising condition ( i.e. , AIDS , hematological malignancy , bone marrow transplantation , immunosuppressive therapy ) receive ≥ 40 mg prednisone per day administer continuously &gt; 14 day prior study start Has history moderate severe hypersensitivity allergic reaction betalactam ( βlactam ) antibacterial , include cephalosporin , carbapenems , penicillin , βlactamase inhibitor , metronidazole , nitroimidazole derivative Is receive receive disulfiram within 14 day receive study drug currently receive probenecid Has participate clinical study investigational product within 30 day prior first dose study drug Has previously participate study ceftolozane MK7625A .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>